Tyrosine-specific protein kinases play crucial roles in transducing signals that regulate a diversity of cellular responses, including proliferation and differentiation. Protein tyrosine kinases are further implicated in neoplastic transformation by the finding that a disproportionate number of oncogenes are mutated versions of normal cellular tyrosine kinases. Cellular transformation by these oncogenes is accompanied by an increased and/or altered profile of intracellular phosphotyrosyl-proteins. These observations suggest that protein tyrosine kinases represent potential targets for a novel class of low molecular weight inhibitors directed at the signaling pathways involved in initiation and maintenance of the transformed state. We hypothesize that an effective approach to the discovery of novel anti-tumor agents will be to identify natural products with selective inhibitory effects on protein tyrosine kinase activities. To identify new protein tyrosine kinase inhibitors, we will screen extracts from higher plants using an in vitro tyrosine kinase assay. Plant extracts will be analyzed for their abilities to inhibit exogenous substrate phosphorylation by cell membranes containing the oncogenic tyrosine kinase, pp6O(v-src). Subsequently, this assay will be used to direct the isolation of active tyrosine kinase inhibitors from the crude extracts. In related studies, in vitro assays will be employed to assess the effects of limited chemical modifications of active compounds on the potency and selectivity of kinase inhibition. Active tyrosine kinase inhibitors will be further evaluated as inhibitors of protein tyrosine phosphorylation and cellular proliferation in vivo using a non-transformed, growth factor-dependent, myeloid progenitor cell line and transformed, growth factor-independent sub-lines expressing oncogenic tyrosine kinases. The ultimate goal of these studies will be to characterize novel lead compounds with selective inhibitory effects on both oncogenic tyrosine kinase activities and the un- controlled growth of cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA052995-01
Application #
3813289
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Ihle, N T; Powis, G; Kopetz, S (2011) PI-3-Kinase inhibitors in colorectal cancer. Curr Cancer Drug Targets 11:190-8
Liu, Enbo; Knutzen, Christine A; Krauss, Sybille et al. (2011) Control of mTORC1 signaling by the Opitz syndrome protein MID1. Proc Natl Acad Sci U S A 108:8680-5
Gwak, Ho-Shin; Shingu, Takashi; Chumbalkar, Vaibhav et al. (2011) Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int J Cancer 128:787-96
Leone, Marilisa; Barile, Elisa; Vazquez, Jesus et al. (2010) NMR-based design and evaluation of novel bidentate inhibitors of the protein tyrosine phosphatase YopH. Chem Biol Drug Des 76:10-6
Ihle, Nathan T; Powis, Garth (2010) The biological effects of isoform-specific PI3-kinase inhibition. Curr Opin Drug Discov Devel 13:41-9
Koul, Dimpy; Shen, Ruijun; Kim, Yong-Wan et al. (2010) Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 12:559-69
Ihle, Nathan T; Powis, Garth (2010) Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol Aspects Med 31:135-44
Ihle, Nathan T; Lemos, Robert; Schwartz, David et al. (2009) Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Mol Cancer Ther 8:94-100
Ihle, Nathan T; Lemos Jr, Robert; Wipf, Peter et al. (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69:143-50
Katiyar, Samiksha; Liu, Enbo; Knutzen, Christine A et al. (2009) REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase. EMBO Rep 10:866-72

Showing the most recent 10 out of 14 publications